Key Investor Signals
Secured DKK 4.2M through BII Venture Lab in 2026
Equilibrium Diagnostics was selected for BioInnovation Institute’s 2026 Venture Lab Cohort 10, which provides DKK 4.2M in convertible financing and 12 months of venture-building support.
uAPI added prognostic value across multiple patient cohorts
A 2026 preprint validated uAPI in three independent chronic kidney disease cohorts and additional type 2 diabetes cohorts, adding prognostic information beyond established kidney-risk models.
Patent-backed technology from Aarhus University
The company is built on Aarhus University-developed technology covered by patent applications for the urine analyzer and its use in predicting kidney disease progression.
Other Positive Signals
- A 2024 peer-reviewed JASN study linked lower urine acid-base scores to faster decline across three CKD cohorts.
- Innovation Fund Denmark awarded Innobooster support for German validation and EU regulatory preparation.
- A DKK 1.6M Augustinus Foundation grant funded international validation of the urine acid/base biomarker.
- Currently offers urine acid-base assessment services for research studies.
- A 2025 Nordic health-economics model estimated €75M in annual Danish savings from uAPI-based CKD risk stratification.
Team
Lars Svane
CEO and Co-founder
- Senior Innovation Coach with the BioMedical Design Novo Nordisk Foundation Fellowship, supporting need-driven health innovation and clinical validation.
- Special Consultant at Aarhus University’s Department of Clinical Medicine / BioMedical Design
- Worked with the MedTech Innovation Center on commercialization, including international sales and marketing for medical-equipment businesses.
Mads Vaarby Sørensen
CTO and Co-founder
- PhD in medicine from Aarhus University, with a research career focused on renal physiology, electrolyte handling and acid-base biology.
- Associate Professor at Aarhus University following postdoctoral research and an Aarhus Institute of Advanced Studies fellowship.
- Co-author of the 2024 JASN study linking the urine acid/base score to CKD progression across development, variation and validation cohorts.
Peder Berg
CMO and Co-founder
- Physician-scientist and kidney researcher at Aarhus University focused on renal physiology, acid-base balance and tubular function.
- Received a 2024 Aarhus University Research Foundation PhD Award for work on urine-based assessment of kidney and CFTR function.
- Co-author of the 2024 JASN urine acid/base score study in chronic kidney disease.
Product
Equilibrium Diagnostics is developing a urine-based kidney diagnostic built around the AP Reader and the urine Ammonium–pH Index (uAPI). The AP Reader measures urinary ammonium and pH from a single sample, and uAPI combines those measurements into a score designed to complement eGFR and albuminuria; the current AP Reader is positioned for research laboratories.
Measuring kidney tubular function directly
The AP Reader measures urinary ammonium and pH to assess how well the kidney tubules handle acid, adding information that standard kidney filtration and albumin-leakage measures do not directly capture.
Automated urine testing workflow
The AP Reader is an automated laboratory analyser designed to measure the two urine parameters reproducibly and fit into research and clinical laboratory workflows.
A single score for progression risk
uAPI combines urinary ammonium and pH into one score. Published CKD research links lower scores to faster progression, supporting its development for risk stratification and monitoring alongside standard kidney tests.
Market Overview
Chronic kidney disease often progresses without symptoms and remains widely undiagnosed. More than 850M people are estimated to be affected worldwide. In the U.S., over 35M adults have CKD, yet around 9 in 10 do not know they have it. This diagnostic gap can delay risk assessment, monitoring and referral.
Kidney-care guidelines use eGFR, urine albumin and validated kidney-failure risk equations to guide monitoring and specialist referral. The underlying tests primarily reflect filtration and glomerular damage. Equilibrium Diagnostics is developing a complementary urine test that adds information on tubular function and progression risk.
Estimated number of people worldwide affected by CKD, according to the National Kidney Foundation.
Share of U.S. adults with CKD who are unaware they have it, according to the CDC.
Estimated global market in 2025, projected to reach about $1.8B by 2033.
Cost of treating U.S. Medicare beneficiaries with CKD in 2022.
Comparable Outcomes
Astute Medical
Astute Medical developed NEPHROCHECK, a urine biomarker test that assesses the risk of acute kidney injury using two protein biomarkers.\n\nbioMérieux acquired Astute Medical in April 2018 for approximately $90M in cash.
Exosome Diagnostics
Exosome Diagnostics developed a urine test that reads tumor RNA carried in extracellular vesicles released by prostate cancer cells.\n\nBio-Techne completed its acquisition of Exosome Diagnostics in August 2018 for $250M upfront.
Interested in More Startups Like Equilibrium Diagnostics?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.